Carson Advisory Inc. Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Carson Advisory Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 13.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,039 shares of the company’s stock after acquiring an additional 127 shares during the period. Carson Advisory Inc.’s holdings in Eli Lilly and Company were worth $921,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Rovin Capital UT ADV grew its position in Eli Lilly and Company by 60.7% during the 3rd quarter. Rovin Capital UT ADV now owns 405 shares of the company’s stock valued at $359,000 after purchasing an additional 153 shares during the last quarter. Washington Trust Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 1.7% in the third quarter. Washington Trust Advisors Inc. now owns 1,051 shares of the company’s stock worth $931,000 after buying an additional 18 shares in the last quarter. Windward Capital Management Co. CA purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $378,000. Shoker Investment Counsel Inc. grew its holdings in shares of Eli Lilly and Company by 2.0% during the third quarter. Shoker Investment Counsel Inc. now owns 679 shares of the company’s stock valued at $602,000 after buying an additional 13 shares during the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $5,378,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $831.74 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a 50-day simple moving average of $896.31 and a two-hundred day simple moving average of $867.53. The firm has a market capitalization of $789.59 billion, a PE ratio of 89.92, a P/E/G ratio of 2.94 and a beta of 0.43. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same period in the prior year, the company posted $0.10 earnings per share. The company’s revenue was up 20.4% compared to the same quarter last year. Analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.63%. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. Barclays cut their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,008.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.